secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stem Cell Inc. (—)
CIK:        0001828613
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001477932-23-007948
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stem Cell Inc. acquires spinal cord injury therapy tech from related party for 2M shares; appoints Dr. Anand as CSO
--------------------------------------------------------------------------------

- Acquired stem cell-based Spinal Cord Injury Therapy Technology from Auto Stem Laboratories for 2M shares of common stock.
- Appointed Dr. Anand Kumar Arachimani as director and CSO effective Oct 1, 2023; he is also managing director of Auto Stem Labs (related party).
- Company changed name from Global Gold Royalty, Inc. to Stem Cell Inc. effective Oct 10, 2023, via shareholder vote.
- Board expects the acquisition to shift focus from precious metals to stem cell regenerative medicine biotechnology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828613/000147793223007948/0001477932-23-007948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828613/000147793223007948/global_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-23-007948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer